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Abstract
Purpose To estimate the maximum tolerated dose (MTD) and/or identify the recommended Phase II dose (RP2D) for com-
bined INC280 and buparlisib in patients with recurrent glioblastoma with homozygous phosphatase and tensin homolog 
(PTEN) deletion, mutation or protein loss.
Methods This multicenter, open-label, Phase Ib/II study included adult patients with glioblastoma with mesenchymal-epi-
thelial transcription factor (c-Met) amplification. In Phase Ib, patients received INC280 as capsules or tablets in combination 
with buparlisib. In Phase II, patients received INC280 only. Response was assessed centrally using Response Assessment in 
Neuro-Oncology response criteria for high-grade gliomas. All adverse events (AEs) were recorded and graded.
Results 33 patients entered Phase Ib, 32 with altered PTEN. RP2D was not declared due to potential drug–drug interactions, 
which may have resulted in lack of efficacy; thus, Phase II, including 10 patients, was continued with INC280 monotherapy 
only. Best response was stable disease in 30% of patients. In the selected patient population, enrollment was halted due to 
limited activity with INC280 monotherapy. In Phase Ib, the most common treatment-related AEs were fatigue (36.4%), nausea 
(30.3%) and increased alanine aminotransferase (30.3%). MTD was identified at INC280 Tab 300 mg twice daily + buparlisib 
80 mg once daily. In Phase II, the most common AEs were headache (40.0%), constipation (30.0%), fatigue (30.0%) and 
increased lipase (30.0%).
Conclusion The combination of INC280/buparlisib resulted in no clear activity in patients with recurrent PTEN-deficient 
glioblastoma. More stringent molecular selection strategies might produce better outcomes.
Trial registration: NCT01870726.
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Introduction
Glioblastomas are the most common type of brain tumor and 
generally have a limited response to available therapies [1]. 
Even when optimally managed with combined chemo-irra-
diation, patients with glioblastomas have poor outcomes [2] 
with a median survival of 14–16 months in study cohorts. 
Available options for recurrent or progressive tumors are 
limited and novel therapeutic options are urgently needed. 
Glioblastoma growth is driven by aberrant activity of one or 
more signaling pathways. Dysregulation of the proto-onco-
gene MET (c-Met), and the phosphatidylinositol 3-kinase 
(PI3K) signaling pathways are frequent in glioblastoma 
[3, 4]. Preclinical and translational studies have indicated 
that activation of MET and PI3K signaling are important 
in tumor initiation and maintenance [5]. Inhibition of MET 
can have potent anti-tumor effects, including regression of 
human glioblastoma tumor xenografts [6, 7]. Loss of phos-
phatase and tensin homolog (PTEN), a negative regulator 
of PI3K, by mutation or gene deletion is the most common 
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form of PI3K pathway dysregulation, occurring in around 
25–44% of all glioblastomas [3, 8]. With complex genetic 
alterations in glioblastomas, blocking only one pathway may 
be insufficient to fully impede cancer cell growth, thus, com-
bining therapies that strategically target multiple pathways 
may improve clinical outcomes in patients who fail first- or 
second-line treatment for recurrent glioblastoma.
In preclinical models, buparlisib (BKM120), a PI3K 
inhibitor, has been combined with INC280 (capmatinib), a 
MET inhibitor, and synergy between the two agents has been 
observed in PTEN-null glioblastoma cell lines that express 
hepatocyte growth factor (HGF; data not shown). In addi-
tion, in an in vivo model of a human glioblastoma xenograft 
with a PTEN mutation and HGF expression (presumably 
leading to autocrine MET activation), the combination of 
these two agents was significantly more efficacious than 
either agent alone (Supplemental Fig. 1). INC280 has also 
demonstrated preclinical and clinical activity in tumors with 
MET dysregulation [9–12]. Buparlisib has demonstrated 
activity in tumors with PI3K activation [13–15].
Here we report results from a multicenter, open-label, 
Phase Ib/II study. The aim of the Phase Ib part was to esti-
mate the maximum tolerated dose (MTD) and/or to identify 
the recommended Phase II dose (RP2D) for the combination 
of INC280 and buparlisib, followed by the Phase II part to 
assess the clinical efficacy of INC280 as a single agent and 
in combination with buparlisib, and to further assess the 
safety.
In addition, a surgical arm (which comprised patients 
that were candidates for surgical resection) was planned to 
determine the pharmacokinetic/pharmacodynamic (PK/PD) 
profile of the study drug combination in patients undergoing 
tumor resection for recurrent glioblastoma after 7 to 10 days 
of treatment. Because the RP2D for the combination was not 
declared, the Phase II was conducted with INC280 mono-
therapy only.
Materials and methods
Study design and conduct
For the Phase Ib part, adults (≥ 18 years) with recurrent 
glioblastoma and documented homozygous PTEN dele-
tion, PTEN mutation or protein loss assessed with immu-
nohistochemistry (IHC) for PTEN (H score < 10) were 
eligible for enrollment in this study, which was confirmed 
by local documentation or central assessment. For the 
Phase II part, patients were pre-screened for MET veri-
fied centrally by fluorescence in situ hybridization (FISH) 
first and, if the gene copy number (GCN) was > 5, were 
allocated to the INC280 single agent arm. Patients with 
tumours harbouring fusion transcripts or mutant MET 
were eligible after documented agreement with the spon-
sor. Patients with GCN ≤ 5 were pre-screened for PTEN 
and were planned to be allocated to the combination arm 
of INC280 with buparlisib (although this arm was never 
activated; Supplemental Fig. 2).
Phase I single agent trials have determined the MTD 
and RP2D of buparlisib to be 100 mg/day [16, 17]. Addi-
tional key inclusion criteria were Eastern Cooperative 
Oncology Group performance status (ECOG PS) ≤ 2; 
histologically confirmed glioblastoma regardless of IDH 
status, radiologically proven relapse according to the 
Response Assessment in Neuro-Oncology (RANO) cri-
teria [18], ≤ 2 prior systemic therapies; prior treatment 
with vascular endothelial growth factor (VEGF) directed 
therapy was allowed. Key exclusion criteria included 
pregnancy, prior/current treatment with MET inhibitor or 
HGF-targeted therapy, prior/current PI3K inhibitors, or 
mammalian target of rapamycin (mTOR) inhibitors, active 
cardiac disease or other cardiac abnormalities, gastrointes-
tinal disease or impairment that could significantly alter 
drug absorption, and history of psychological impairment.
In the Phase Ib part, patients were enrolled into one of 
six dosing cohorts based on human safety, PK and preclin-
ical PK-efficacy data to receive INC280 as either oral cap-
sules (Cap) or tablets (Tab). The film-coated Tab formula-
tion was developed to improve patient convenience and 
consequently, compliance. The Tab formulation provides 
higher exposure than the Cap; the Tab dose was calculated 
to achieve a comparable exposure rate to the INC280 Cap. 
Dose escalation of the combination treatment was guided 
by a Bayesian logistic regression model (BLRM) in order 
to monitor patient safety. The switch from INC280 Cap to 
Tab occurred at the start of cohort 5.
The protocol was amended during Phase Ib to allow for 
a change in local pre-screening to be performed during the 
dose escalation; a threshold for PTEN negativity of an H 
score < 10 for PTEN IHC was introduced to align with the 
threshold currently used by the central laboratory that was 
based on the medical literature [19].
All patients in Phase II received INC280 monotherapy 
over a 28-day cycle. Treatment continued until unaccepta-
ble toxicity, disease progression or discontinuation at the 
discretion of the Investigator, or by withdrawal of patient 
consent. Dose adjustments were permitted to manage treat-
ment-related toxicities.
A protocol amendment was also made during Phase II 
of the study in which an INC280-monotherapy arm was 
introduced to investigate single-agent INC280 in glio-
blastoma patients with altered MET (amplified GCN > 5, 
fusion or mutant). The inclusion criterion was modified 
to add ‘MET amplification by FISH (fusion transcripts 
or mutant MET may be eligible after discussion with the 
sponsor)’.
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Primary objectives
The primary objective of Phase Ib was to establish the MTD 
and to identify the RP2D for the combination of INC280 
and buparlisib. The primary objective of Phase II was to 
assess the clinical efficacy and safety of INC280 alone and 
in combination with buparlisib; and for the surgical arm, the 
objective was to determine the PK/PD characteristics of the 
combination of INC280 and buparlisib. This analysis was 
not performed, as the Phase II part was limited to INC280 
monotherapy in MET-amplified glioblastoma based on PK 
findings of Phase Ib.
Assessments
Tumor response and progression was assessed using the 
RANO Working Group response criteria for high-grade 
gliomas [18]. The radiological evaluation was reviewed 
centrally. Magnetic resonance imaging and clinical presen-
tation were evaluated at baseline and repeated at 8-week 
intervals during the study until disease progression, the start 
of another antineoplastic treatment, or death.
All adverse events (AEs) were recorded and graded 
according to the Common Terminology Criteria for AEs 
(CTCAE) version 4.03 at every visit. AE monitoring con-
tinued for at least 30 days following the last dose of study 
treatment. Complete physical examinations and assessment 
of vital signs were performed on scheduled days. When 
dose-limiting toxicity (DLT) occurred, study treatment was 
interrupted and the toxicity was managed according to pre-
specified criteria. Blood samples were collected for INC280 
and buparlisib PK analysis.
Results
Patient characteristics
Patient demographics and baseline characteristics
In Phase Ib, patients (n = 33) were primarily male (72.7%), 
Caucasian (87.9%), with a median age of 59.0  years 
(Table 1). All except one patient had altered PTEN (dele-
tion, mutation or protein loss). One patient had PTEN-pos-
itive IHC and no PI3K mutations, but was included based 
on detection of MET amplification by the investigator’s 
institution. Patients were entered into one of the following 
dose cohorts: INC280 Cap 200, 400, or 500 mg twice daily 
(BID) + 50 mg buparlisib once daily (QD); INC280 Cap 
500 mg BID + 80 mg buparlisib QD; or INC280 Tab 300 or 
400 mg BID + 80 mg buparlisib QD.
Ten patients entered the INC280 monotherapy arm (Phase 
II) (median age 48 years; 70% women, 90% Caucasian; 
Table 1). From 1st June 2015, 148 patients were screened 
for entry into the Phase II of this study; 10 patients (6.76%) 
were treated.
Biomarkers
In Phase II, patients had a range of MET gene copy num-
ber and co-occurring genetic alterations assessed by next 
generation sequencing (NGS using the Foundation Medi-
cine T7 panel; summarized in Table 2). Further analysis of 
MET copy number status by NGS in 9 of the 10 Phase II 
patients revealed that 7/9 showed broad copy number gain of 
a chromosomal region containing the MET gene, with copy 
numbers in the range of 4 to 6. Only 2/9 tumors (Patients 
002 and 004) showed evidence for focal amplification of 
the MET gene, with copy number ≥ 9. In line with these 
observations, the two tumors with focal MET amplification 
displayed a MET:CEP-7 ratio in the FISH assay of around 
5. This ratio was lower (average ~ 1.7) in the 7 tumors with 
broad copy number gain, with the exception of one tumor 
(Patient 010) with a marked discrepancy between copy num-
ber by FISH and NGS (20 vs. 4 without any evidence of 
focality in either case). Despite the selection of MET FISH 
copy number ≥ 5, MET protein expression, as assessed by 
IHC, was relatively low across tumor samples (Fig. 1). The 
range of MET gene copy numbers and genetic alterations in 
the Phase Ib is shown in Table 3.
Table 1  Patient demographics and baseline characteristics
Characteristic Phase Ib 
INC280 + buparlisib 
(all patients)
Phase II INC280
400 mg BID Tab
N 33 10
Median age, years (range) 59.0 (27–75) 48.0 (32–63)
Sex: male, n (%) 24 (72.7) 3 (30.0)
Race, n (%)
  Black 1 (3.0) 0
 Caucasian 29 (87.9) 9 (90.0)
 Other 3 (9.1) 0
 Unknown 0 1 (10.0)
ECOG PS, n (%)
 0 13 (39.4) 3 (30.0)
 1 18 (54.5) 5 (50.0)
 2 2 (6.1) 2 (20.0)
Type of last antineoplastic therapy, n (%)
 Medication 27 (81.8) 7 (70.0)
 Radiotherapy 1 (3.0) 1 (10.0)
 Surgery 5 (15.2) 2 (20.0)
 Journal of Neuro-Oncology
1 3
Safety
Phase Ib dose escalation
All 33 patients in Phase Ib discontinued study treatment and 
reported at least one AE. The main reason for study dis-
continuation was disease progression (n = 29, 87.9%); other 
reasons were AEs (n = 2) and consent withdrawal/patient 
decision (n = 2). Treatment-related AEs were reported 
in 84.8% of the Phase Ib patients. The most commonly 
reported treatment-related AEs were fatigue (36.4%), nau-
sea (30.3%), alanine aminotransferase increased (30.3%), 
aspartate aminotransferase increased (24.2%), depression 
(24.2%) and hyperglycemia (21.2%). Grade ≥ 3 AEs were 
reported in 24 patients (72.7%). Treatment-related grade ≥ 3 
AEs were reported in 12 patients (36.4%). MTD was identi-
fied at INC280 Tab 300 mg BID + buparlisib 80 mg QD, a 
dosage received by 7 patients. DLT was observed in four 
patients: nausea (INC280 Tab 300 mg BID + buparlisib 
80 mg QD; grade 3), personality change (INC280 Cap 
400 mg BID + buparlisib 50 mg QD; grade 3), and elevated 
transaminases in two patients (both INC280 Tab 400 mg 
BID + buparlisib 80 mg QD; grade 3; Table 4).
Phase II
As in Phase Ib, all patients in Phase II reported at least one 
AE. Treatment-related AEs were reported in 60.0% of the 
Phase II patients. The most commonly reported AEs by pre-
ferred term were headache (40.0%), constipation (30.0%), 
fatigue (30.0%) and increased lipase (30.0%). Grade ≥ 3 AEs 
were reported in nine patients (90.0%). Treatment-related 
grade ≥ 3 AEs were reported two patients (20.0%).
In terms of exposure to INC280, the average mean daily 
dose (± standard deviation, SD) for all patients in the Phase 
II part of this study was 754.1 mg (± 125.21), with a cumula-
tive dose of 54,220.0 mg (± 43,045.24).
Table 2  NGS data with potential (known or likely) functional significance (Phase II data)
FISH fluorescent in situ hybridization (for MET gene copy number in the nuclei), FM foundation medicine, ID patient identification number, 
IHC immunohistochemical staining score, H score (of MET protein expression at the plasma membrane or in the cytoplasm), N/A not applicable, 
N/F no findings, PD progressive disease, SD stable disease, UNK unknown
a Clinical PD, the lesions were not assessed
b Ratio of MET copies to CEP7 copies
c Ratio of the size of genomic fragment overlapping with MET relative to the size of the MET gene
d Two different segments overlapping the MET gene were called by the analysis pipeline downstream of the hybridization capture and NGS pro-
cess [31]
e Note discrepancy and high copy number by FISH which does not correlate with NGS data and may represent a potential technical issue with 
FISH
Patient ID Best 
overall 
response
IHC FISH FM NGS Sequencing data with potential (known or likely) functional significance
MET 
copy 
number
Ratiob MET 
Copy 
Number
Ratioc Copy number variant 
(copy number)
Short variant rearrangement
001 PD 32 5.59 1.19 5 612.1 KDR(13), KIT(13), 
PDGFRA(13)
ATRX, EPHA6, H3F3A, 
HSP90AA1, TP53
N/F
002 SD 40 11.63 4.86 9 1.0 CDK4(95), IGF1R(10), 
MET(9)
ATRX, IDH1, TP53 N/F
14d 0.4d
003 PD 117 6.56 2.51 5 154.1 CDK4(63),GLI1(22), 
MYCN(35), TP53(0)
ATRX, IDH1 N/F
004 PD 100 12.62 5.21 16 1.5 CDKN2A(0), 
CDKN2B(0), 
MET(18)
AR, NF1, NPM1, PIK3R1, 
PRDM1
N/F
005 PD 5 5.12 1.26 3 1258.1 PTEN, TERT, TP53 KEAP1
006 PD 112 6.38 1.85 6 63.5 KDR(10), KIT(11), 
PDGFRA(40), 
TP53(0)
CDKN2A, FANCL, LZTR1, 
PIK3CA, TERT
PDGFRA
6d 29.4d
007 SD 0 8 1.41 4 396.3 EGFR(107) ARAF, BCL2, CDKN2A EGFR
008 UNKa 3 7.84 3.27 N/A N/A EGFR, NF1, PTEN N/F
009 SD 0 5.12 1.08 6 1258.1 CDK4(29) KMT2C, NF1, TERT, TP53 N/F
010 PD 33 20e 2.5 4 1205.6 N/F APC, ATRX, NF1, PTEN, RB1, 
TP53
FAT1
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Pharmacokinetics
During Phase Ib, the target exposures for both drugs in the 
combination therapy were not met in the combination treat-
ment arm. Compared with data from single-agent treatment 
studies, the exposures of INC280 and buparlisib were sig-
nificantly lower when dosed in combination (Table 5). Com-
pared with single-agent INC280 (CINC280A2201, data on 
file), the area under the curve (AUC) of INC280 400 mg BID 
in combination with buparlisib 80 mg QID was 0.73-fold. 
Compared with single-agent buparlisib [17], the AUC of 
buparlisib 80 mg QD in combination with INC280 400 mg 
BID was 0.38-fold. The mechanism for this reduced expo-
sure is not known at present but the possibility of drug–drug 
interaction cannot be ignored. AUCs and other pharmacoki-
netic parameters are presented in Table 5.
Efficacy
Overall efficacy
The combination of INC280 + buparlisib demonstrated very 
limited activity in these 33 patients with PTEN-altered glio-
blastoma. RP2D was not declared due to potential drug–drug 
interactions and hence a low drug exposure, which may have 
resulted in lack of observed efficacy with the INC280 and 
buparlisib drug combination in Phase Ib. Consequently, the 
combination arms planned for Phase II were not initiated.
In the Phase II INC280 monotherapy arm, 10 patients 
were enrolled. No patient achieved partial (PR) or com-
plete response (CR). Best response of stable disease (SD) 
was observed in 3 of 10 patients (30.0%) in Phase II, 
and lasted between 16–20 weeks from the start of treat-
ment until disease progression, similar to the exposure 
time (Fig. 1). Due to the limited activity observed with 
INC280 monotherapy (400 mg BID Tab) in this population 
of patients with recurrent glioblastoma, the enrollment of 
patients was halted early after pre-planned futility analysis 
and the primary endpoint, progression-free survival rate at 
6 months, was not assessed due to insufficient sample size.
Efficacy according to biomarkers
All alterations identified and key co-occurring genetic 
alterations as identified by NGS are shown in Table 2. 
Alterations in several genes previously linked to glioblas-
toma (e.g. PTEN, TP53, EGFR) [3] were detected, along 
with other mutations of unknown significance.
Fig. 1  Most frequent somatic genetic alterations observed in tumor 
samples with known/likely functional significance using Next Gen-
eration Sequencing analysis and duration of exposure. Phase II sub-
jects only; two (or more) alterations were observed with known/likely 
functional significance; ATRX, ATP-dependent helicase ATRX, BOR 
best overall response, CDK4 cyclin dependent kinase 4, CDKN2A 
cyclin-dependent kinase inhibitor 2A, EGFR epidermal growth fac-
tor receptor, FISH fluorescent in  situ hybridization (for MET gene 
copy number in the nuclei), ID patient identification number, IDH1 
isocitrate dehydrogenase 1, IHC immunohistochemical staining score 
(of MET protein expression at the plasma membrane or in the cyto-
plasm), KDR kinase insert domain receptor, KIT receptor tyrosine 
kinase protein KIT, MET tyrosine-protein kinase MET, NF1 neurofi-
bromatosis type 1, PD progressive disease, PDGFRA platelet-derived 
growth factor receptor alpha, PTEN phosphatase and tensin homolog, 
TERT telomerase reverse transcriptase, SD stable disease, TP53, 
tumor protein p53, UNK unknown
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Table 3  NGS data with potential (known or likely) functional significance (Phase Ib data)
FISH fluorescent in situ hybridization (for MET gene copy number in the nuclei), FM foundation medicine, ID patient identification number, 
IHC immunohistochemical staining score, H score (of MET protein expression at the plasma membrane or in the cytoplasm), PD progressive 
disease, SD stable disease, UNK unknown
a Clinical PD, the lesions were not assessed
b Ratio of MET copies to CEP7 copies
c Ratio of the size of genomic fragment overlapping with MET relative to the size of the MET gene
d Note discrepancy and high copy number by FISH which does not correlate with NGS data and may represent a potential technical issue with 
FISH
* Patient achieved stable disease (SD) at Cycle 1, Day 15; by Day 27 of Cycle 1, this patient was assessed to have progressive disease (PD)
Patient ID Best 
overall 
response
IHC Sequencing data with potential (known or likely) functional significance
Copy number variant (copy number) Short variant Rearrangement
101 PD 0
102 PD 50 CDK4 (78), GLI1 (18), MDM2 (70), SOX2 
(7)
PTEN, TERT
103 PD CDK4 (36), MDM2 (65) PTEN, TERT
104 PD 80 CDKN2A (0), CDKN2B (0), EGFR (128) AXL, EGFR, FLT4, KDM5A, TERT
105 PD 90 EGFR (61), ERRFI1 (0) EGFR, PTEN, TERT CDKN2A, EGFR
106 PD 100
107 PD ARID1A, FGFR2, PTEN, STAG2
108 PD CDKN2A (0), CDKN2B (0), EGFR (110) EGFR, FAT1, NOTCH1, PTEN, SPTA1, 
TERT
EGFR
109 PD 101 CDKN2A (0), CDKN2B (0) FGFR4, NF1, PTEN, RB1, TERT, TP53 NF1
110 PD 100 CDKN2A (0), CDKN2B (0), EGFR (59) EGFR, PTEN, TERT
111 PD CDKN2A (0), CDKN2B (0), EGFR (46), 
MDM4 (28), PIK3C2B (30)
EGFR, PTEN, TERT EGFR
112 PD 90 RB1 (0) NF1, PTEN, TERT
113 PD 50 CDKN2A (0), CDKN2B (0), MDM4 (53), 
PIK3C2B (54)
BRCA2, PTEN, STAG2, TERT EGFR
114 UNK 80 CDKN2A (0), CDKN2B (0), EGFR (40) PTEN, TERT
115 PD CDKN2A (0) PTEN
116 PD 100 CDKN2A (0), CDKN2C (0), KDR (6), KIT 
(6), PDGFRA (6), PTEN (0)
TERT, TP53
117 PD 110 NF1, PIK3CA, PTEN, RB1, TP53
118 PD TP53 (0) PTEN, TERT
119 PD 0 CDKN2A (0), CDKN2B (0), EGFR (60) TERT
120 PD 0 CCND2 (45), CDK4 (47), EGFR (16), FGF23 
(10), FGF6 (10), FRS2 (102), MDM2 (93)
PTEN, TERT
121 PD 0 CDKN2A (0), CDKN2B (0), EGFR (45) LRP1B, PTEN, TERT EGFR
122 PD 55
123 PD 80 CDKN2A (0), CDKN2B (0), EGFR (92) EGFR, TERT EGFR
124 PD 100 CDKN2A (0), CDKN2B (0) PTEN, STAG2, TERT
125 PD 30 STK11, TERT
126 PD
127 PD 65 PTEN, TERT
128 SD* 100 CDK4 (61), KIT (6), PDGFRA (6) TP53
129 PD 100 CDKN2A (0), CDKN2B (0), EGFR (125) EGFR EGFR
130 UNK
131 PD 90 CDKN2A (0) BCOR
132 PD 100 CDKN2A (0), CDKN2B (0), EGFR (72) EGFR, GLI1, PTEN, TERT
133 UNK 0 CDKN2A (0), CDKN2B (0), EGFR (42), 
JUN (9), PTEN (0)
EGFR, TERT EGFR
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Discussion
This study was initially based on the hypothesis that 
INC280 and buparlisib would have a synergistic anti-
tumor activity in recurrent glioblastoma with concomi-
tant MET and PI3K activation. The safety profile of the 
combination of INC280 and buparlisib was consistent with 
the known safety profile of these agents as monotherapies 
in the oncology setting [10, 11, 20–22] No new safety 
signals were identified. One patient experienced a per-
sonality change, which is consistent with the know safety 
profile of buparlisib [20]. RP2D was not declared due to a 
lack of efficacy in the drug combination, low drug expo-
sure and potential drug–drug interactions in the Phase Ib 
stage of this trial.
During the conduct of this trial, INC280 film-coated 
Tabs were introduced into the study to improve patient 
convenience, based on a relative bioavailability study (data 
Table 4  Dose-limiting toxicities 
by dose
BID twice daily, DLT dose limiting toxicity, QD once a day
Cohort Total daily doses INC280 
(BID) + buparlisib (QD)
No. of patients 
treated
No. of patients in the dose-
determining set
No. of DLTs 
in cycle 1
INC280 capsule formulation
 1 200 mg + 50 mg 5 4 0
 2 400 mg + 50 mg 6 5 1
 3 500 mg + 50 mg 4 3 0
 4 500 mg + 80 mg 6 4 0
INC280 tablet formulation
 5 300 mg + 80 mg 7 7 1
 6 400 mg + 80 mg 5 4 2
Table 5  Primary pharmacokinetic parameters for INC280 and for buparlisib (Phase 1b data)
Geometric mean AUCtau, ss of INC280 tablet 400 mg bid is 21,000 ng*hr/mL in monotherapy (INC280 IB v6);
Geometric mean AUCtau, ss of buparlisib 80 mg qd is 19,100 ng*hr/mL in monotherapy (BKM120 IB v10)
Vertical, heavy line indicates the INC280 Cap vs Tab treatments
AUC area under the curve, BID twice daily, bup buparlisib, cap capsule, Cmax maximum (peak) observed drug concentration, INC INC280, QD 
once daily, tab tablet
Cycle 1, Day 15 INC 200 mg Cap 
BID + bup 50 mg 
QD
INC 400 mg Cap 
BID + bup 50 mg 
QD
INC 500 mg Cap 
BID + bup 50 mg 
QD
INC 500 mg Cap 
BID + bup 80 mg 
QD
INC 300 mg Tab 
BID + bup 80 mg 
QD
INC 400 mg Tab 
BID + bup 80 mg 
QD
INC280
 N 5 4 3 2 3 4
 AUC tau (h*ng/
mL)
6260 8580 12,800 2650 12,200 15,300
 Geo-mean (Geo-
CV%)
(45) (79) (99) (46) (33) (19)
 Cmax (ng/mL) 1350 1850 3400 494 3460 3870
 Geo-mean (Geo-
CV%)
(59) (78) (114) (71) (39) (55)
Buparlisib
 N 5 5 3 2 4 4
 AUC tau (h*ng/
mL)
8210 5190 6270 10,047 9950 7180
 Geo-mean (Geo-
CV%)
(33) (50) (18) (61) (13) (39)
 N 5 5 3 2 5 4
 Cmax (ng/mL) 680 429 580 779 853 799
 Geo-mean (Geo-
CV%)
(13) (38) (29) (19) (28) (67)
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on file) in which INC280 Tabs were shown to provide 
higher drug exposure than Caps.
Originally, it was not thought that INC280 or buparlisib 
would have sufficient single-agent activity to block can-
cer cell growth due to the complex genetic alterations in 
glioblastoma. However, while Phase Ib of this trial was in 
progress, INC280 showed preliminary efficacy signals in 
two patients with MET amplified recurrent glioblastoma in 
other trials (unpublished data on file and a patient receiving 
compassionate use of INC280 + inhibitor LDE225). Addi-
tionally, INC280 has shown promising clinical efficacy in 
non-small-cell lung carcinoma with MET amplification [10]. 
Based on this emerging clinical evidence, the decision was 
made to continue with a monotherapy arm only in Phase II 
to investigate single-agent INC280 in MET amplified glio-
blastoma patients. For this part of the study, patients were 
enrolled if their tumors showed a relative MET copy number 
of ≥ 5, as measured using a FISH assay.
No evidence of activity was observed with INC280 
monotherapy in Phase II. However, the majority of Phase II 
patients had tumors with elevated MET copy number in the 
context of broad gain of chromosome 7. In addition, MET 
protein expression in those tumor samples, as measured by 
IHC, was relatively low despite increased MET gene copy 
numbers (Table 2).
The discrepancy between MET copy number (FISH) and 
protein expression (IHC) is one that requires careful consid-
eration and highlights the challenges of defining molecular 
inclusion criteria for clinical trials. Given the small sample 
size it is difficult to determine the cause of the apparent dis-
crepancy between gene copy number and protein expression. 
Several possible explanations exist. Sample age may have 
played a role in the low IHC results as all samples were from 
archival material (mean [SD] sample age for Phase II of 
514 [± 359] days). Discordance between FISH and IHC has 
been described before for other cancers [23–26]. Moreover, 
simple chromosome polysomy does not necessarily lead to 
increased transcription.
Significant heterogeneity regarding co-occurring genetic 
alterations was observed across the 10 patients with pre-
sumed MET amplification (Table 2). The detected altera-
tions are consistent with the previously described glioblas-
toma landscape [3].
Recent and ongoing trials of INC280 in lung cancer 
and hepatocellular carcinoma are exploring the predictive 
markers that are suggested by preclinical data. So far, MET 
exon 14 skipping mutations in lung cancer are emerging 
as the most robust predictive marker, and the clinical data 
suggest that both MET copy number and protein overex-
pression may have predictive value as well, but appropriate 
cut-offs still need to be established [10, 27, 28] MET exon 
14 skipping mutations have also recently been reported in 
secondary glioblastoma with a frequency of ~ 14%, and at 
lower frequencies in primary glioblastoma and low-grade 
glioma [29]. In addition, PTPRZ1-MET fusions were found 
in secondary glioblastoma, where they can co-occur with 
MET exon 14 skipping mutations [7, 29]. PTPRZ1-MET 
and other MET fusions were also reported in pediatric glio-
blastoma [30]. Preclinical as well as emerging clinical data 
suggest that brain malignancies with MET mutations and/or 
fusions are responsive to MET inhibitors [29, 30]. Therefore, 
optimizing patient selection for investigation of INC280 in 
glioblastoma may require a more comprehensive characteri-
zation of MET molecular abnormalities beyond copy num-
ber. Another potential predictive biomarker that should be 
considered in future trials of MET inhibitors in glioblastoma 
is HGF expression by the tumor, based on preclinical data 
[12]. While there is good rationale for targeting MET in glio-
blastoma, our study illustrates the need for further molecular 
profiling to identify the subset of patients who may benefit.
INC280 has shown some degree of brain penetration in 
preclinical species (our unpublished observation), but the 
extent of brain exposure and MET inhibition in patients with 
glioblastomas are unknown and may also have affected out-
come. Future trials on novel agents should study this sys-
tematically early on in the clinical trial program to ensure 
the target is reached.
To conclude, the combination INC280/buparlisib resulted 
in reduced exposure of both drugs and no clear signal of 
activity in recurrent PTEN-deficient glioblastoma. With 
the assay and cut-off for MET amplification used, no clear 
activity signal was seen with INC280 single-agent treatment. 
However, consideration of confounding factors and a more 
stringent molecular selection strategy could be used to fur-
ther explore the role of MET inhibitors for the treatment of 
recurrent glioblastoma.
Study limitations
This study is limited by the lack of data available on the 
MET GCN cut-off number for molecular selection. We 
used ≤ 5 as a cut-off based on limited emerging data from 
other capmatinib trials, and, due to the relatively small 
and potentially molecularly diverse patient population, we 
were unable to refine this copy number in the current study. 
This molecular-based therapy uses ‘historical information’ 
because all biopsies to determine MET status were archival, 
without accounting for the effects of intervening therapy or 
molecular drift. Thus, it is possible the molecular profile at 
study entry differed from that extrapolated from the analysis 
of archival tissue.
Acknowledgements This study (CINC280X2204) is funded by 
Novartis Institutes for Biomedical Research (China). The authors 
would like to acknowledge the assistance of all investigators, clinical 
Journal of Neuro-Oncology 
1 3
trial staff, participants and past and present INC280 EPT members. 
The authors thank Paul Coyle, Vicki Betts, PhD, Jackie Johnson, PhD, 
and Gillian Brodie, MSc, of Novartis Ireland Ltd for providing medi-
cal writing support/editorial support, which was funded by Novartis 
Pharma AG, Basel, Switzerland in accordance with Good Publication 
Practice (GPP3) guidelines (https ://www.ismpp .org/gpp3).
Funding This study is funded by Novartis Institutes for Biomedi-
cal Research (China). A.B. Lassman was supported in part by grants 
P30CA013696 and UG1CA189960 from the NCI.
Compliance with ethical standards 
Conflicts of interest In relation to this presentation, we declare the fol-
lowing, real or perceived conflicts of interest: M. van den Bent has 
received grants from Abbvie, and honoraria from Cellgene, BMS, 
Boehringer, AGIOS and VaXIMM. A. Azaro has received consulting 
fees from Orion Pharmaceuticals and Amcure GmbH. F. De Vos has 
received financial support for conducting clinical trials from Novartis, 
BMS, AbbVie and Bioclin. J.M. Sepulveda has received consulting 
fees from Celgene, Pfizer and Abbvie; he has received research grants 
from Pfizer and Catalysis. W.K.A. Yung holds stocks in DNATrix; he 
has received honoraria from DNATrix and Boehringer Ingelheim; he 
holds patents, royalties and/or intellectual property in, and has partici-
pated in a consulting or advisory role for DNATrix; he has received 
travel and/or accommodation expenses from Boehringer Ingelheim. 
P. Wen has received grants/research support from Lilly USA, Agios, 
AstraZeneca, Beigene, Eli Lily, Immunocellular Therapeutics, Ka-
zai, Kadmon, Karyopharm, Merck, Novartis, Oncoceutics, Vascular 
Biogenics and Vaccines; he has received speaker’s bureau fees from 
Merck; he has received consultant/advisory board fees from Genen-
tech/Roche, Taiho Oncology, Novartis, Agios Pharmaceuticals Inc, 
Merck, Puma, Abbvie, AstraZeneca, Eli Lilly, GW Pharmaceuticals, 
Immunomic Therapeutics, Kadmon, Vascular Biogenics, Ziopharm, 
Monteris and Tocagen. A. Lassman reports grants and non-financial 
support from Novartis, during the conduct of the study; personal fees 
and non-financial support from Orbus, grants, personal fees and non-
financial support from Karyopharm, personal fees and non-financial 
support from NW Biotherapeutics, grants and non-financial support 
from Oncoceutics, personal fees and non-financial support from Agios, 
personal fees and non-financial support from Celgene, personal fees 
and non-financial support from Novocure, non-financial support from 
Tocagen, non-financial support from BMS, grants, personal fees and 
non-financial support from Kadmon, grants and non-financial support 
from Genentech/Roche, grants and non-financial support from Amgen, 
grants and non-financial support from Millenium, non-financial sup-
port from Celldex, grants and non-financial support from Pfizer, non-
financial support from Keryx/Aeterna Zentaris, grants and non-finan-
cial support from VBI Vaccines, grants and non-financial support from 
Beigene, personal fees from Bioclinica as an expert blinded independ-
ent reviewer of clinical and imaging data for a BMS-sponsored trial, 
personal fees from prIME Oncology, personal fees and non-financial 
support from Sapience, personal fees from WebMD, personal fees and 
non-financial support from Physicians’ Education Resource, personal 
fees from Cortice, grants, personal fees and non-financial support from 
AbbVie, personal fees and non-financial support from Forma, personal 
fees and non-financial support from Bayer, grants and non-financial 
support from Global Coalition for Adaptive Research, personal fees 
and non-financial support from American Society of Clinical Oncol-
ogy, grants and non-financial support from QED, grants, personal fees 
and non-financial support from NCI, non-financial support from New 
York University, grants and non-financial support from NRG Oncolo-
gy/RTOG-Foundations, grants from UCLA, grants from Northwestern 
University, grants from James S. McDonnell Foundation, non-financial 
support from Yale University, non-financial support from Radiological 
Society of North America, non-financial support from FDA, personal 
fees from Italian Foundation for Cancer Research, personal fees and 
non-financial support from Abbott Molecular, and personal fees from 
Elsevier, outside the submitted work M. Joerger has received grants 
from BMS and AstraZeneca. G. Tabatabai has served on Advisory 
Boards for AbbVie and BMS, has received research/travel grants from 
Medac, Novocure and Roche Diagnostics, and has received speaker`s 
fees from Meda and Novocure. J. Rodon reports non-financial sup-
port and reasonable reimbursement for travel from European Journal 
of Cancer, Vall d’Hebron Institut of Oncology, Chinese University of 
Hong Kong, SOLTI, Elsevier, GlaxoSmithKline; receiving consulting 
and travel fees from Novartis, Eli Lilly, Orion Pharmaceuticals, Servier 
Pharmaceuticals, Peptomyc, Merck Sharp & Dohme, Kelun Pharma-
ceutical/Klus Pharma, Spectrum Pharmaceuticals Inc, Pfizer, Roche 
Pharmaceuticals, Ellipses Pharma (including serving on the scientific 
advisory board from 2015-present), receiving research funding from 
Bayer and Novartis, and serving as investigator in clinical trials with 
Spectrum Pharmaceuticals, Tocagen, Symphogen, BioAtla, Pfizer, 
GenMab, CytomX, Kelun-Biotech, Takeda-Millenium, GlaxoSmith-
Kline, IPSEN and travel fees from ESMO, US Department of Defense, 
Louissiana State University, Hunstman Cancer Institute, Cancer Core 
Europe, Karolinska Cancer Institute and King Abdullah International 
Medical Research Center (KAIMRC). R. Tiedt, T. Kirsilae and S. Vi-
cente are employees of Novartis Pharma AG. S. Zhao is an employee 
of Novartis Institutes for Biomedical Research (China). A. Balbin is 
an employee of Novartis Institutes for Biomedical Research (US). H. 
Zhang is an employee of Novartis and holds shares with Novartis. W. 
Wick receives study support to the institution from Apogenix, Pfizer 
and Roche.
Ethical approval The study protocol and all amendments were reviewed 
by the Independent Ethics Committee or Institutional Review Board 
for each center. All procedures performed in studies involving human 
participants were in accordance with the ethical standards of the insti-
tutional and/or national research committee and with the 1964 Helsinki 
declaration and its later amendments or comparable ethical standards.
Informed consent Informed consent was obtained from all individual 
participants or appropriate surrogates included in the study. Additional 
information on the study was provided verbally by the study investiga-
tor or in a written format.
Open Access This article is distributed under the terms of the Crea-
tive Commons Attribution 4.0 International License (http://creat iveco 
mmons .org/licen ses/by/4.0/), which permits unrestricted use, distribu-
tion, and reproduction in any medium, provided you give appropriate 
credit to the original author(s) and the source, provide a link to the 
Creative Commons license, and indicate if changes were made.
References
 1. McFaline-Figueroa JR, Lee EQ (2018) Brain tumors. Am J Med 
131(8):874–882
 2. Stupp R, Mason WP, van den Bent MJ et al (2005) Radiotherapy 
plus concomitant and adjuvant temozolomide for glioblastoma. N 
Engl J Med. 352(10):987–996
 3. Brennan CW, Verhaak RG, McKenna A, Campos B, Noushmehr 
H, Salama SR, Zheng S, Chakravarty D, Sanborn JZ, Berman 
SH, Beroukhim R et al (2013) The somatic genomic landscape of 
glioblastoma. Cell 155(2):462–477
 Journal of Neuro-Oncology
1 3
 4. Tasaki T, Fujita M, Okuda T et al (2016) MET expressed in 
glioma stem cells is a potent therapeutic target for glioblastoma 
multiforme. Anticancer Res. 36(7):3571–3577
 5. Malla R, Gopinath S, Alapati K et al (2010) Downregulation of uPAR and 
cathepsin B induces apoptosis via regulation of Bcl-2 and Bax and inhi-
bition of the PI3K/Akt pathway in gliomas. PLoS ONE 5(10):e13731
 6. Abounader R, Lal B, Luddy C et al (2002) In vivo targeting of 
SF/HGF and c-met expression via U1snRNA/ribozymes inhibits 
glioma growth and angiogenesis and promotes apoptosis. FASEB 
J 16(1):108–110
 7. Bao ZS, Chen HM, Yang MY et al (2014) RNA-seq of 272 glio-
mas revealed a novel, recurrent PTPRZ1-MET fusion transcript 
in secondary glioblastomas. Genome Res 24(11):1765–1773
 8. Wang SI, Puc J, Li J et al (1997) Somatic mutations of PTEN in 
glioblastoma multiforme. Cancer Res 57(19):4183–4186
 9. Liu X, Wang Q, Yang G et al (2011) A novel kinase inhibitor, 
INCB28060, blocks c-MET-dependent signaling, neoplastic 
activities, and cross-talk with EGFR and HER-3. Clin Cancer 
Res 17(22):7127–7138
 10. Schuler M, Berardi R, Lim WT et al (2016) Phase I study of the 
safety and efficacy of the cMET inhibitor capmatinib (INC280) 
in patients with advanced cMET + NSCLC. Paper presented at 
Multidisciplinary symposium on thoracic oncology, 22–24 Sep-
tember 2016, Chicago, IL
 11. Wu YL, Zhang L, Kim DW et al (2018) Phase Ib/II study of cap-
matinib (INC280) Plus gefitinib after failure of epidermal growth 
factor receptor (EGFR) inhibitor therapy in patients with EGFR-
mutated, MET factor-dysregulated non-small-cell lung cancer. J 
Clin Oncol 36(31):3101–3109
 12. Baltschukat S, Schacher Engstler B, Huang A et al (2019) Cap-
matinib (INC280) Is active against models of non-small cell lung 
cancer and other cancer types with defined mechanisms of MET 
activation. Clin Cancer Res 25(10):3164–3175
 13. Matas-Cespedes A, Rodriguez V, Kalko SG et al (2014) Disrup-
tion of follicular dendritic cells-follicular lymphoma cross-talk by 
the pan-PI3K inhibitor BKM120 (Buparlisib). Clin Cancer Res 
20(13):3458–3471
 14. Netland IA, Forde HE, Sleire L et al (2016) Treatment with the 
PI3K inhibitor buparlisib (NVP-BKM120) suppresses the growth 
of established patient-derived GBM xenografts and prolongs sur-
vival in nude rats. J Neurooncol 129(1):57–66
 15. Wen PY, Touat M, Alexander BM et al (2019) Buparlisib in 
patients with recurrent glioblastoma harboring phosphatidylino-
sitol 3-kinase pathway activation: an Open-Label, Multicenter, 
Multi-Arm Phase II Trial. J Clin Oncol 37(9):741–750
 16. Ando Y, Inada-Inoue M, Mitsuma A et al (2014) Phase I dose-
escalation study of buparlisib (BKM120), an oral pan-class I PI3K 
inhibitor, in Japanese patients with advanced solid tumors. Cancer 
Sci 105(3):347–353
 17. Bendell JC, Rodon J, Burris HA et al (2012) Phase I, dose-esca-
lation study of BKM120, an oral pan-Class I PI3K inhibitor, in 
patients with advanced solid tumors. J Clin Oncol 30(3):282–290
 18. Wen PY, Macdonald DR, Reardon DA et al (2010) Updated response 
assessment criteria for high-grade gliomas: response assessment in 
neuro-oncology working group. J Clin Oncol 28(11):1963–1972
 19. Kim B, Myung JK, Seo JH et al (2010) The clinicopathologic 
values of the molecules associated with the main pathogenesis of 
the glioblastoma. J Neurol Sci 294(1–2):112–118
 20. Vansteenkiste JF, Canon JL, De Braud F et al (2015) Safety and 
efficacy of buparlisib (BKM120) in patients with PI3K pathway-
activated non-small cell lung Cancer: results from the Phase II 
BASALT-1 Study. J Thorac Oncol 10(9):1319–1327
 21. Tanwandee T, Sukeepaisarnjaroen W, Lam Chan S et al (2016) 
A phase (Ph) II study of the efficacy and safety of the cMET 
inhibitor capmatinib (INC280) in patients (pts) with advanced 
hepatocellular carcinoma (HCC). Paper presented at Journal of 
Clinical Oncology
 22. Wolf J (2018) Results of the GEOMETRY mono-1 phase II study 
for evaluation of the MET inhibitor capmatinib (INC280) in patients 
with MET exon-14 skipping mutated advanced non-small cell lung 
cancer. Abstract #LBA52. Paper presented at: European Society of 
Medical Oncology (ESMO), 19–23 October 2018, Munich, Germany
 23. Kotani H, Ebi H, Kitai H et al (2016) Co-active receptor tyrosine 
kinases mitigate the effect of FGFR inhibitors in FGFR1-ampli-
fied lung cancers with low FGFR1 protein expression. Oncogene 
35(27):3587–3597
 24. Ilie MI, Bence C, Hofman V et al (2015) Discrepancies between 
FISH and immunohistochemistry for assessment of the ALK sta-
tus are associated with ALK ‘borderline’-positive rearrangements 
or a high copy number: a potential major issue for anti-ALK thera-
peutic strategies. Ann Oncol 26(1):238–244
 25. Yan B, Yau EX, Bte Omar SS et al (2010) A study of HER2 
gene amplification and protein expression in gastric cancer. J Clin 
Pathol 63(9):839–842
 26. Cabillic F, Gros A, Dugay F et al (2014) Parallel FISH and immu-
nohistochemical studies of ALK status in 3244 non-small-cell lung 
cancers reveal major discordances. J Thorac Oncol 9(3):295–306
 27. Bang YJ et al (2014) Phase I study of the safety and efficacy of 
INC280 in patients with advanced MET-dependent solid tumours. 
Abstract 25202014
 28. Wolf J, Seto T, Han J-T et al (2018) Results of the GEOMETRY 
mono-1 phase II study for evaluation of the MET inhibitor capmatinib 
(INC280) in patients (pts) with MET ex14 mutated advanced non-
small cell lung cancer (NSCLC). Paper presented at ESMO2018
 29. Hu H, Mu Q, Bao Z et al (2018) Mutational landscape of second-
ary glioblastoma guides MET-targeted trial in brain tumor. Cell 
175(6):1665–1678.e18
 30. International Cancer Genome Consortium PedBrain Tumor Pro-
ject (2016) Recurrent MET fusion genes represent a drug target 
in pediatric glioblastoma. Nat Med 22(11):1314–1320
 31. Frampton GM, Fichtenholtz A, Otto GA et al (2013) Develop-
ment and validation of a clinical cancer genomic profiling test 
based on massively parallel DNA sequencing. Nat Biotechnol 
31(11):1023–1031
Publisher’s Note Springer Nature remains neutral with regard to 
jurisdictional claims in published maps and institutional affiliations.
Journal of Neuro-Oncology 
1 3
Affiliations
Martin van den Bent1  · Analia Azaro2 · Filip De Vos3 · Juan Sepulveda4 · W. K. Alfred Yung5 · Patrick Y. Wen6 · 
Andrew B. Lassman7 · Markus Joerger8 · Ghazaleh Tabatabai9 · Jordi Rodon5 · Ralph Tiedt10 · Sylvia Zhao11 · 
Tiina Kirsilae10 · Yi Cheng11 · Sergio Vicente10 · O. Alejandro Balbin12 · Hefei Zhang11 · Wolfgang Wick13
1 Erasmus University Medical Center (MC) Cancer Institute, 
Rotterdam, The Netherlands
2 Molecular Therapeutics Research Unit (UITM), Department 
of Medical Oncology, Vall d’Hebron University Hospital, 
Barcelona, Spain
3 University Medical Center Utrecht, Utrecht, The Netherlands
4 Hospital Universitario, 12 de Octubre, Madrid, Spain
5 MD Anderson Cancer Center, Houston, TX, USA
6 Center for Neuro-Oncology, Dana-Farber Cancer Institute 
and Harvard Medical School, Boston, MA, USA
7 Department of Neurology and Herbert Irving Comprehensive 
Cancer Center, Columbia University Irving Medical Center, 
New York, NY, USA
8 Cantonal Hospital, St. Gallen, Switzerland
9 Interdisciplinary Division of Neuro-Oncology, Center 
for CNS Tumors, Comprehensive Cancer Center, University 
Hospital Tübingen, Hertie Institute for Clinical Brain 
Research & Eberhard Karls University Tübingen, German 
Cancer Consortium (DKTK), DKFZ Partner Site Tübingen, 
Tübingen, Germany
10 Novartis Pharma AG, Basel, Switzerland
11 Novartis Institutes for Biomedical Research (China), 
Shanghai, China
12 Novartis Institutes for Biomedical Research (United States), 
Boston, MA, USA
13 Clinical Cooperation Unit Neurooncology, German Cancer 
Consortium (DKTK), German Cancer Research Center 
(DKFZ), and Neurology Clinic and National Center 
for Tumor Diseases, University Hospital Heidelberg, 
Heidelberg, Germany
